Previous 10 | Next 10 |
CF Acquisition (NASDAQ:CFVIU) +28% on deal to take conservative video platform Rumble public Phunware (NASDAQ:PHUN) +23%. Digital World Acquisition (NASDAQ:DWAC) +23% on deal to take conservative video platform Rumble public Omeros (NASDAQ:OMER) +18% to sell OMID...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com News moving stocks today include earnings rep...
Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk. A U.S. Court of Appeals for the Federal Circuit panel affirmed a previous ruling by the U.S. Patent and Trademark Offi...
The recent volatility on Wall Street continued during Wednesday's session, as fears about the Omicron variant continued to weigh on sentiment. Travel stocks felt the brunt of this concern, with United Airlines (NASDAQ:UAL), Delta Air Lines (NYSE:DAL), Carnival (NYSE:CCL), Alaska Air Group (NY...
Initial reports from Reuters and Bloomberg have cited the first signs of the Omnicron variant hitting U.S. shores. The Centers For Disease Control have identified the first case of the Omicron variant in California, US. According to reports from Bloomberg, the CDC explained that the individ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arbutus Biopharma (NASDAQ: ABUS ) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (NASDAQ: MRNA ). Source: Shutterstock The good news for Arbutus Biopharm...
Shares of Roivant Sciences (ROIV +33.8%) are surging thanks to Arbutus Biopharma's (ABUS +68.0%) patent dispute win over Moderna (MRNA -7.7%). As of last month, Roivant owns 29.1% of Arbutus common shares. Roivant made a $116M strategic investment in Arbutus in October 2017. Seeking Alpha con...
3 Penny Stocks to Watch in December That Exploded Today If you’re looking for penny stocks that could explode or have exploded, there are plenty of options to choose from. But, to pick the best penny stocks to buy , investors need to have a thorough understanding of what ...
Preliminary data from a phase 1 trial of Arbutus Biopharma's (ABUS +77.3%) AB-836 found that the drug was safe, well tolerated, and had robust antiviral activity against chronic hepatitis B virus ("HBV"). The trial has completed two of three parts. The first evaluated alternating single ...
Gainers: Arbutus Biopharma (NASDAQ:ABUS) +87%. MDJM (NASDAQ:MDJH) +41%. Context Therapeutics (NASDAQ:CNTX) +35%. Build-A-Bear Workshop (NYSE:BBW) +33%. Ardelyx (NASDAQ:ARDX) +28%. Ambarella (NASDAQ:AMBA) +25%. Roivant Sciences (NASDAQ:ROIV) +22%. Stran & Company (NASDAQ:STRN) +20%. Marpai...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...